Researchers pointed to GLP-1s as a potential contributing factor, alongside pandemic-related shifts in behaviors. And while these medications may be helping address the nation’s obesity epidemic ...

Several medical societies and health care professionals have addressed concerns about safety of off-brand GLP-1s. In January 2024, The Obesity Society, Obesity Action Coalition and Obesity ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing ...